Association between the chemokine receptor 5 delta32 polymorphism and rheumatoid arthritis: a meta-analysis

REFERENCES

• Choi SJ, Rho YH, Ji JD, Song GG, Lee YH. Genome scan meta-analysis of rheumatoid arthritis. Rheumatology (Oxford). 2006; 45:166–70.
   PubMed Web of Science ®Google Scholar
• Prakken B, Albani S, Martini A. Juvenile idiopathic arthritis. Lancet. 2011;377:2138–49.
   Google Scholar
• Szekanecz Z, Kim J, Koch AE. Chemokines and chemokine receptors in rheumatoid arthritis. Semin Immunol. 2003;15: 15–21.
   Google Scholar
• Kim HR, Park MK, Cho ML, Kim KW, Oh HJ, Park JS, Heo YM, Lee SH, Kim HY, Park SH. Induction of macrophage migration inhibitory factor in ConA-stimulated rheumatoid arthritis syno-vial fibroblasts through the P38 map kinase-dependent signaling pathway. Korean J Intern Med. 2010;25:317–26.
   PubMedGoogle Scholar
• Wu L, LaRosa G, Kassam N, Gordon CJ, Heath H, Ruffing N, Chen H, Humblias J, Samson M, Parmentier M, Moore JP, Mackay CR. Interaction of chemokine receptor CCR5 with its ligands: multiple domains for HIV-1 gp120 binding and a single domain for chemokine binding. J Exp Med. 1997;186:1373–81.
   PubMed Web of Science ®Google Scholar
• Wedderburn LR, Robinson N, Patel A, Varsani H, Woo P. Selective recruitment of polarized T cells expressing CCR5 and CXCR3 to the inflamed joints of children with juvenile idiopathic arthritis. Arthritis Rheum. 2000;43: 765–74.
   Google Scholar
• Liu R, Paxton WA, Choe S, Ceradini D, Martin SR, Horuk R, MacDonald ME, Stuhlmann H, Koup RA, Landau NR. Homo-zygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell. 1996;86:367–77.
   PubMed Web of Science ®Google Scholar
• Benkirane M, Jin DY, Chun RF, Koup RA, Jeang KT. Mecha-nism of transdominant inhibition of CCR5-mediated HIV-1 infection by ccr5delta32. J Biol Chem. 1997;272: 30603–6.
   Google Scholar
• Rossol M, Pierer M, Arnold S, Keysser G, Burkhardt H, Baer-wald C, Wagner U. Negative association of the chemokine receptor CCR5 d32 polymorphism with systemic inflammatory response, extra-articular symptoms and joint erosion in rheuma-toid arthritis. Arthritis Res Ther. 2009;11:R91.
   Google Scholar
• Scheibel I, Veit T, Neves AG, Souza L, Prezzi S, Machado S, Kohem C, Icarelli M, Xavier R, Brenol JC, Chies JA. Differential CCR5delta32 allelic frequencies in juvenile idiopathic arthritis subtypes: evidence for different regulatory roles of CCR5 in rheumatological diseases. Scand J Rheumatol. 2008;37: 13–7.
   Google Scholar
• Lindner E, Nordang GB, Melum E, Flato B, Selvaag AM, Thorsby E, Kvien TK, Forre OT, Lie BA. Lack of association between the chemokine receptor 5 polymorphism CCR5delta32 in rheumatoid arthritis and juvenile idiopathic arthritis. BMC Med Genet. 2007;8: 33.
   Google Scholar
• Pokorny V, McQueen F, Yeoman S, Merriman M, Merriman A, Harrison A, Highton J, McLean L. Evidence for negative asso-ciation of the chemokine receptor CCR5 d32 polymorphism with rheumatoid arthritis. Ann Rheum Dis. 2005;64:487–90.
   PubMedGoogle Scholar
• Zuniga JA, Villarreal-Garza C, Flores E, Barquera R, Perez-Hernandez N, Montes de Oca JV, Cardiel MH, Vargas-Alarcon G, Granados J. Biological relevance of the polymorphism in the CCR5 gene in refractory and non-refractory rheumatoid arthritis in Mexicans. Clin Exp Rheumatol. 2003;21:351–4.
   Google Scholar
• Zapico I, Coto E, Rodriguez A, Alvarez C, Tone JC, Alvarez V. CCR5 (chemokine receptor-5) DNA-polymorphism influences the severity of rheumatoid arthritis. Genes Immun. 2000;1:288–9.
   PubMed Web of Science ®Google Scholar
• Gomez-Reino JJ, Pablos JL, Carreira PE, Santiago B, Serrano L, Vicario JL, Balsa A, Figueroa M, de Juan MD. Association of rheumatoid arthritis with a functional chemokine receptor, CCR5. Arthritis Rheum. 1999;42: 989–92.
   Google Scholar
• Cooke SP, Forrest G, Venables PJ, Hajeer A. The delta32 dele-tion of CCR5 receptor in rheumatoid arthritis. Arthritis Rheum. 1998;41:1135–6.
   PubMedGoogle Scholar
• Gaffed P, Madsen HO, Petersen J, Marquart H, Hansen TM, Freiesleben Sorensen S, Volck B, Svejgaard A, Andersen V. CC chemokine receptor 5 polymorphism in rheumatoid arthritis. J Rheumatol. 1998;25: 1462–5.
   Google Scholar
• Lee YH, Rho YH, Choi SJ, Ji JD, Song GG, Nath SK, Harley JB. The PTPN22 C1858T functional polymorphism and autoimmunediseases-a meta-analysis. Rheumatology (Oxford). 2007;46: 49–56.
   Google Scholar
• Lee YH, Harley JB, Nath SK. Meta-analysis of TNF-alpha pro-moter -308 A/G polymorphism and SLE susceptibility. Eur J Hum Genet. 2006;14: 364–71.
   Google Scholar
• Lee YH, Rho YH, Choi SJ, Ji JD, Song GG. Association of TNF-alpha -308 G/A polymorphism with responsiveness to TNF-alpha-blockers in rheumatoid arthritis: a meta-analysis. Rheu-matol Int. 2006;27: 157–61.
   Google Scholar
• Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315: 629–34.
   PubMed Web of Science ®Google Scholar
• Davey Smith G, Egger M. Meta-analyses of randomised con-trolled trials. Lancet. 1997;350:1182.
   PubMed Web of Science ®Google Scholar
• DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177–88.
   PubMed Web of Science ®Google Scholar
• Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21:1539–58.
   PubMed Web of Science ®Google Scholar
• Shieh B, Liau YE, Hsieh PS, Yan YP, Wang ST, Li C. Influence of nucleotide polymorphisms in the CCR2 gene and the CCR5 promoter on the expression of cell surface CCR5 and CXCR4. Int Immunol. 2000;12:1311–8.
   PubMedGoogle Scholar
• Kohem CL, Brenol JC, Xavier RM, Bredemeier M, Brenol CV, Dedavid e Silva TL, de Castilhos Mello A, Canedo AD, Neves AG, Chies JA. The chemokine receptor CCR5 genetic polymor-phism and expression in rheumatoid arthritis patients. Scand J Rheumatol. 2007;36: 359–64.
   Google Scholar
• Prahalad S, Bohnsack JF, Jorde LB, Whiting A, Clifford B, Dunn D, Weiss R, Moroldo M, Thompson SD, Glass DN, Bamshad MJ. Association of two functional polymorphisms in the CCR5 gene with juvenile rheumatoid arthritis. Genes Immun. 2006;7: 468–75.
   Google Scholar
• Martens HA, Gross S, van der Steege G, Brouwer E, Berden JH, de Sevaux R, Derksen RH, Voskuyl AE, Berger SP, Navis GJ, Kallenberg CG, Bijl M. Lack of association of C-C chemokine receptor 5 Delta32 deletion status with rheumatoid arthritis, systemic lupus erythematosus, lupus nephritis, and disease severity. J Rheumatol. 2010;37: 2226–31.
   Google Scholar
• Hinks A, Martin P, Flynn E, Eyre S, Packham J, Barton A, Worthington J, Thomson W. Association of the CCR5 gene with juvenile idiopathic arthritis. Genes Immun. 2010;11:584–9.
   PubMedGoogle Scholar
• Lee YH, Rho YH, Choi SJ, Ji JD, Song GG. PADI4 polymor-phisms and rheumatoid arthritis susceptibility: a meta-analysis. Rheumatol Int. 2007;27: 827–33.
   Google Scholar
• Qin S, Rottman JB, Myers P, Kassam N, Weinblatt M, Loetscher M, Koch AE, Moser B, Mackay CR. The chemokine receptors CXCR3 and CCR5 mark subsets of T cells associated with certain inflammatory reactions. J Clin Invest. 1998;101: 746–54.
   Google Scholar
• Suzuki N, Nakajima A, Yoshino S, Matsushima K, Yagita H, Okumura K. Selective accumulation of CCR5+ T lymphocytes into inflamed joints of rheumatoid arthritis. Int Immunol. 1999; 11:553–9.
   PubMed Web of Science ®Google Scholar
• van Kuijk AW, Vergunst CE, Gerlag DM, Bresnihan B, Gomez-Reino JJ, Rouzier R, Verschueren PC, van de Leij C, Maas M, Kraan MC, Tak PP. CCR5 blockade in rheumatoid arthritis: a randomised, double-blind, placebo-controlled clinical trial. Ann Rheum Dis. 2010;69: 2013–6.
   Google Scholar
• Prahalad S. Negative association between the chemokine receptor CCR5-Delta32 polymorphism and rheumatoid arthritis: a meta-analysis. Genes Immun. 2006;7:264–8.
   PubMed Web of Science ®Google Scholar